The novelty of this work is the association of DAMPs (HMGB1) and inflammatory mediators (IL-8, IL-10, IL1-β, and MCP-1) in the development of systemic inflammatory response (SIRS) in pediatric patients with newly diagnosed acute lymphoblastic leukemia (ALL) and no apparent clinical infection. Here, CCL2 is linked to systemic inflammatory response syndrome.